Media Releases

Expanding choice and adaptive care in automated insulin delivery for people with type 1 diabetes

Burgdorf, Switzerland, 3 June 2026 – mylife Diabetes Care, CamDiab, and Dexcom announce the integration of the Dexcom G7 Continuous Glucose Monitoring (CGM) system into the myLoop automated insulin delivery (AID) system, powered by the CamAPS FX app. The integration expands sensor compatibility within myLoop and enables people living with type 1 diabetes to benefit from Dexcom G7’s fast^{^,1-4} warm-up time and proven accuracy^5-6, while offering greater choice and flexibility in their daily therapy.

“Our goal is to empower people with type 1 diabetes with greater choice and seamless usability,” said Sébastien Delarive, Chief Executive Officer of mylife Diabetes Care. “Integrating Dexcom G7 into myLoop is another step towards a more flexible and personalised AID experience that adapts to individual needs.”

Dexcom G7 offers users a simple yet powerful way to support their diabetes management. Its low-profile, all-in-one wearable offers ease of use and a fast warm-up time^{^,1-4}, supporting a smooth experience within myLoop.

myLoop integrates the YpsoPump insulin pump, the CamAPS FX app, and compatible sensors for continuous glucose monitoring. The close technical collaboration between Dexcom and CamDiab, in partnership with mylife Diabetes Care, made it possible to add Dexcom G7 to the smartphone-based myLoop ecosystem. Together, mylife Diabetes Care, CamDiab and Dexcom continue to advance adaptive solutions designed to support glycaemic management and help reduce the demands of diabetes care.

“Empowering people to manage their diabetes with confidence is central to our commitment to the diabetes community,” said Matt Dolan, executive vice president strategy and corporate development, at Dexcom. “Our long-standing partnership with mylife Diabetes Care and CamDiab reflects that commitment, and this latest integration brings together proven technologies in an update many users have been looking forward to.”

myLoop is powered by the CamAPS FX app from CamDiab, an advanced and personalised adaptive hybrid closed-loop app that automatically adjusts insulin delivery based on your sensor glucose readings.

“We are proud to see the CamAPS FX algorithm continue to power meaningful advances in automated insulin delivery,” said Professor Roman Hovorka, Founder of CamDiab. “Integrating Dexcom G7 illustrates CamDiab’s commitment to bringing market-leading innovation to users of myLoop and ultimately improving the lives of those living with type 1 diabetes.”

The integration of Dexcom G7 with the myLoop AID system is launching in Switzerland today. Launches in Australia, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Spain, Sweden and the United Kingdom are planned to commence at the end of June, depending on local regulatory approvals.

About mylife Diabetes Care

mylife Diabetes Care is a global diabetes care company based in Switzerland, dedicated to improving life with diabetes by empowering them to gain more freedom through better control. The company focuses on modern automated insulin delivery (AID) solutions designed for people living with diabetes, enabled through close collaboration with healthcare professionals and payers worldwide. For more information, visit www.mylife-diabetescare.com

About DexCom, Inc.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com

About CamDiab Ltd

CamDiab Ltd is a digital health and personalised medicine company focused on the design, development, and commercialisation of its world leading, interoperable CamAPS® FX closed-loop app. CamAPS FX is designed to use an adaptive, self-learning control algorithm, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycaemic control. Since its founding in 2019, its mission has been to help people with type 1 diabetes and their families live better lives. Find out more at www.camdiab.com

Disclaimer

mylife, myLoop, YpsoPump and related brand marks are registered trademarks of mylife Diabetes Care AG or of its affiliates. CamAPS is a registered trademark of CamDiab Ltd. Other trademarks are the property of their respective owners.